An overview of the pharmacotherapeutics for dystonia: advances over the past decade.
1/5 보강
PICO 자동 추출 (휴리스틱, conf 2/4)
유사 논문P · Population 대상 환자/모집단
환자: more widespread dystonia manifestations
I · Intervention 중재 / 시술
추출되지 않음
C · Comparison 대조 / 비교
추출되지 않음
O · Outcome 결과 / 결론
The most novel emerging therapies include daxibotulinumtoxinA, dipraglurant, and sodium oxybate. There is a strong clinical need for more effective therapeutic options in dystonia, which may involve the development of individualized treatment options based on dystonia subtype, etiology, or novel mechanisms of action that target specific underlying contributing features.
[INTRODUCTION] Dystonia is the third most common movement disorder, impacting quality of life and work productivity.
APA
Abu-Hadid O, Jimenez-Shahed J (2022). An overview of the pharmacotherapeutics for dystonia: advances over the past decade.. Expert opinion on pharmacotherapy, 23(17), 1927-1940. https://doi.org/10.1080/14656566.2022.2147823
MLA
Abu-Hadid O, et al.. "An overview of the pharmacotherapeutics for dystonia: advances over the past decade.." Expert opinion on pharmacotherapy, vol. 23, no. 17, 2022, pp. 1927-1940.
PMID
36394521 ↗
Abstract 한글 요약
[INTRODUCTION] Dystonia is the third most common movement disorder, impacting quality of life and work productivity. Its pathogenesis is heterogeneous, and many pharmacotherapeutics have been suggested for its treatment. The mainstay of management for focal dystonia is botulinum toxin. Oral pharmacotherapeutics usually are nonspecific and associated with risk of unwanted side effects such as drowsiness and lethargy. There is tremendous need for robust clinical trials for new pharmacotherapeutics as we deepen our understanding of dystonia.
[AREAS COVERED] This review will focus on the advances and research in the pharmacologic treatment of dystonia from January 2012 to April 2022. We performed a systematic database search on PubMed for the period mentioned.
[EXPERT OPINION] Botulinum toxins remain the mainstay of focal dystonia treatment but may be insufficient for treatment of patients with more widespread dystonia manifestations. The most novel emerging therapies include daxibotulinumtoxinA, dipraglurant, and sodium oxybate. There is a strong clinical need for more effective therapeutic options in dystonia, which may involve the development of individualized treatment options based on dystonia subtype, etiology, or novel mechanisms of action that target specific underlying contributing features.
[AREAS COVERED] This review will focus on the advances and research in the pharmacologic treatment of dystonia from January 2012 to April 2022. We performed a systematic database search on PubMed for the period mentioned.
[EXPERT OPINION] Botulinum toxins remain the mainstay of focal dystonia treatment but may be insufficient for treatment of patients with more widespread dystonia manifestations. The most novel emerging therapies include daxibotulinumtoxinA, dipraglurant, and sodium oxybate. There is a strong clinical need for more effective therapeutic options in dystonia, which may involve the development of individualized treatment options based on dystonia subtype, etiology, or novel mechanisms of action that target specific underlying contributing features.
추출된 의학 개체 (NER)
시술
보툴리눔독소 주사
전체 NER 표 보기
| 유형 | 영어 표현 | 한국어 / 풀이 | UMLS CUI | 출처 | 등장 |
|---|---|---|---|---|---|
| 시술 | botulinum toxin
|
보툴리눔독소 주사 | dict | 1 |
🏷️ 키워드 / MeSH 📖 같은 키워드 OA만
함께 등장하는 도메인
이 논문이 속한 카테고리와 같은 논문에서 자주 함께 다뤄지는 카테고리들
🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반
- A Phase I Study of Hydroxychloroquine and Suba-Itraconazole in Men with Biochemical Relapse of Prostate Cancer (HITMAN-PC): Dose Escalation Results.
- Self-management of male urinary symptoms: qualitative findings from a primary care trial.
- Clinical and Liquid Biomarkers of 20-Year Prostate Cancer Risk in Men Aged 45 to 70 Years.
- Diagnostic accuracy of Ga-PSMA PET/CT versus multiparametric MRI for preoperative pelvic invasion in the patients with prostate cancer.
- Clinical Presentation and Outcomes of Patients Undergoing Surgery for Thyroid Cancer.
- Association of patient health education with the postoperative health related quality of life in low- intermediate recurrence risk differentiated thyroid cancer patients.
📖 비슷한 OA 논문 — 같은 카테고리, 무료 전문 가능
- Mechanisms of Botulinum Toxin Type A Action on Pain.
- Effect of Botulinum Toxin Injection on EMG Activity and Bite Force in Masticatory Muscle Disorder: A Randomized Clinical Trial.
- Botulinum Toxin: An Update on Pharmacology and Newer Products in Development.
- Immunogenicity of botulinum toxin.
- Botulinum Toxin in the Treatment of Headache.